Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong

Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.

Investors Business Daily • Dec 9, 2025

Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More

The Undercovered Dozen spotlights 12 lesser-known stocks and funds with compelling investment theses and recent developments. This week's edition covers articles published between Nov. 28 and Dec. 4, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.

Seeking Alpha • Dec 8, 2025

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45%

Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding any shares of Harrow in the previous quarter.

The Motley Fool • Nov 27, 2025

Harrow to Present at Two Investor Conferences in December

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5 th Annual Ophthalmology Day (Virtual) Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37 th Annual Healthcare Conference (New York, NY) Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Piper Sandler will be webcast live and can be found on the Event's page on the Company's website.

GlobeNewsWire • Nov 24, 2025

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt's product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow's portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes.

GlobeNewsWire • Nov 18, 2025

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Harrow, Inc. ( HROW ) Q3 2025 Earnings Call November 11, 2025 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO & Chairman of the Board Andrew Boll - President, CFO & Corporate Secretary Patrick Sullivan - Head of Commercial Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Thomas Shrader - BTIG, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.

Seeking Alpha • Nov 11, 2025

Harrow Announces Third Quarter 2025 Financial Results

Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

GlobeNewsWire • Nov 10, 2025

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per quarter by Q4 2027, leveraging recent acquisitions and biosimilar partnerships. Despite low profitability and modest cash reserves, HROW's experienced management, robust pipeline, and expanding market share support a bullish long-term outlook.

Seeking Alpha • Nov 5, 2025

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025

GlobeNewsWire • Oct 27, 2025

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth through 2034, with relatively conservative assumptions on margins and product adoption. I reiterate a "Buy" rating for HROW stock, with ~88% upside to a $72.7 base case fair value, including some risk adjustments.

Seeking Alpha • Oct 16, 2025